Alnylam Pharma (ALNY) Tops Q3 EPS by 21c
Tweet
Share
E-mail
Get Alerts ALNY Hot Sheet
Price: $312.78 +3.68%
EPS Growth %: +403.1%
Financial Fact:
Research and development: 83.17M
Today's EPS Names:
CRMT, More
EPS Growth %: +403.1%
Financial Fact:
Research and development: 83.17M
Today's EPS Names:
CRMT, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q3 EPS of ($1.06), $0.21 better than the analyst estimate of ($1.27). Revenue for the quarter came in at $17.1 million versus the consensus estimate of $24.65 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Alnylam Pharmaceuticals (ALNY) PT Lowered to $470 at H.C. Wainwright
- MotorK names Roy Toren to board as Helen Protopapas resigns
- RBC Capital Upgrades GEA Group AG (G1A:GR) (GEAGY) to Outperform
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
